Advanced search
Publication Cover
Infection and Drug Resistance Volume 13, 2020 - Issue
Submit an article Journal homepage
175
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis

Fuzhen Zhang1 Biosafety Level 3 Laboratory, School of Public Health, Southern Medical University, Guangzhou, People’s Republic of China;2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Shanshan Li2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Shuan Wen2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Tingting Zhang2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Yuanyuan Shang2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Fengmin Huo2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Yi Xue2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Ling Li1 Biosafety Level 3 Laboratory, School of Public Health, Southern Medical University, Guangzhou, People’s Republic of China;3 Experimental Teaching Center, School of Basic Medical Science, Southern Medical University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected]
&
Yu Pang2 National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6803-9807
ORCID Icon show all
Pages 815-822 | Published online: 11 Mar 2020

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ravi Singh, Muhammed Shaheer & M. Elizabeth Sobhia. (2023) Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study. Journal of Biomolecular Structure and Dynamics 41:10, pages 4421-4443.
Read now
Stephani L Stancil, Fuad Mirzayev & Susan M Abdel-Rahman. (2021) Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date. Drug Design, Development and Therapy 15, pages 2815-2830.
Read now

Articles from other publishers (10)

Luyao Zheng, Xueting Qi, Weiyan Zhang, Hong Wang, Lei Fu, Bin Wang, Xi Chen, Xiaoyou Chen & Yu Lu. (2023) Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models. Frontiers in Cellular and Infection Microbiology 13.
Crossref
Alessio Lanni, Emanuele Borroni, Angelo Iacobino, Cristina Russo, Leonarda Gentile, Lanfranco Fattorini & Federico Giannoni. (2022) Activity of Drug Combinations against Mycobacterium abscessus Grown in Aerobic and Hypoxic Conditions. Microorganisms 10:7, pages 1421.
Crossref
Saskia E. Mudde, Anna M. Upton, Anne Lenaerts, Hannelore I. Bax & Jurriaan E. M. De Steenwinkel. (2022) Delamanid or pretomanid? A Solomonic judgement!. Journal of Antimicrobial Chemotherapy 77:4, pages 880-902.
Crossref
Huiwen Zheng, Yiting Wang, Wencong He, Feina Li, Hui Xia, Bing Zhao, Shengfen Wang, Chen Shen & Yanlin Zhao. (2022) In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria . Antimicrobial Agents and Chemotherapy 66:1.
Crossref
Sara Occhineri, Tommaso Matucci, Laura Rindi, Giusy Tiseo, Marco Falcone, Niccolò Riccardi & Giorgio Besozzi. (2022) Pretomanid for tuberculosis treatment: an update for clinical purposes. Current Research in Pharmacology and Drug Discovery 3, pages 100128.
Crossref
Priyanshu Singh Raikwar, Manisha Mahapatra, Vipin Singh & Anshu Bhardwaj. 2022. Biology of Mycobacterial Lipids. Biology of Mycobacterial Lipids 27 49 .
Sheng Zeng, Jingran Zhang, Mingwei Sun, Xiaofei Zhang, Gregory M. Cook & Tianyu Zhang. (2021) Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc 1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis . Antimicrobial Agents and Chemotherapy 65:9.
Crossref
Kelly M. Pennington, Ann Vu, Douglas Challener, Christina G. Rivera, F.N.U. Shweta, John D. Zeuli & Zelalem Temesgen. (2021) Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 24, pages 100244.
Crossref
A. V. Kukurika. (2021) Pretomanid: Clinical Trials and Prospects to Be Used in Treatment Regimens for Multiple and Extensive Drug Resistant Tuberculosis. Tuberculosis and Lung Diseases 99:6, pages 54-60.
Crossref
Helianthous Verma, Shekhar Nagar, Shivani Vohra, Shubhanshu Pandey, Devi Lal, Ram Krishan Negi, Rup Lal & Charu Dogra Rawat. (2021) Genome analyses of 174 strains of Mycobacterium tuberculosis provide insight into the evolution of drug resistance and reveal potential drug targets. Microbial Genomics 7:3.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.